Edwards Lifesciences (EW) used its annual investor day to lift its 2025 revenue outlook and lay out fresh 2026 guidance, ...

Edwards Lifesciences’ recent Investor Day outlined upgraded 2025 revenue growth expectations of about 9%–10% and introduced ...

Truist raised the firm’s price target on Edwards Lifesciences (EW) to $92 from $90 and keeps a Hold rating on the shares. The ...

Using ultrasound waves, Cardiawave’s Valvosoft is touted as the first non-invasive treatment for severe symptomatic aortic ...

When a surgical aortic valve prosthesis degenerates, the patient— older, perhaps sicker, and no longer a good candidate for surgery — has a valve-in-valve alternative in the form of transcatheter ...

Among patients with severe isolated aortic stenosis younger than 65, the rate of transcatheter aortic valve replacement (TAVR) now almost matches that of surgical aortic valve replacement (SAVR) ...

Operators continue to disagree on the necessity of conducting a randomized controlled trial of transcatheter aortic valve replacement (TAVR) in people with bicuspid anatomy, a prominent group that had ...

St. Luke’s Structural Heart team is among the first in Pennsylvania to use the ShortCut device, improving safety in complex valve-in-valve TAVR procedures.

Attempts to improve commissural alignment during TAVR with commercially available transcatheter heart valves, a technique that would later facilitate access to the coronary arteries, yield mixed ...

Please provide your email address to receive an email when new articles are posted on . Procedural expertise and equipment have markedly improved since the first transcatheter aortic valve replacement ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio NEW ORLEANS — At 3 years, patients with ...

JenaValve announced new results from an expanded patient cohort supporting the use of its Trilogy transcatheter heart valve ...